Bayer AG achieved a major win at the US Supreme Court, which agreed to review the company's appeal regarding lawsuits claiming its Roundup weedkiller causes cancer. This development sent Bayer's shares soaring by 7% to 44.42 euros in European morning trading.
The core of Bayer's argument is that federal law, specifically the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), preempts state-level failure-to-warn claims. Since US regulators did not require a cancer warning on Roundup's label, the company contends that it cannot be sued for not having one. The Supreme Court's decision to hear this appeal offers a potential resolution to over a decade of litigation that has cost Bayer more than $10 billion and negatively impacted its stock price.
The specific case under review by the Supreme Court involves a $1.25 million Missouri jury verdict for a man who developed non-Hodgkin lymphoma, alleging it was caused by Roundup and that the product should have carried a cancer warning. Bloomberg Intelligence analyst Holly Froum estimates that a favorable ruling for Bayer could impact approximately $787 million in existing Roundup verdicts and eliminate plaintiffs' strongest claim. A Supreme Court decision in Bayer's favor would provide significant regulatory clarity for companies bringing products to market.
Alongside the Supreme Court case, Bayer is also pursuing a proposed $7.25 billion class-action settlement with former Roundup users. This settlement aims to resolve many of the approximately 65,000 outstanding lawsuits. However, the Supreme Court's ruling, expected by early July, could profoundly affect the overall landscape of the Roundup litigation, potentially reducing Bayer's overall liability and offering a path to finally put these legal challenges behind them.
